Bayer Signs a Worldwide Agreement with Roche’s Foundation Medicine to Develop and Commercialize CDx for Cancer

Bayer Signs a Worldwide Agreement with Roche’s Foundation Medicine to Develop and Commercialize CDx for Cancer

Shots:

  • Bayer collaborates with Roche to develop & commercialize NGS-based companion diagnostics for multiple cancer therapies developed by Bayer and covers FMI’s complete portfolio of tests including its Foundation One CDx
  • The companies initiate the collaboration with development of CDx of Vitraki (larotrectinib), a first TRK inhibitor for TRK fusion cancer in all solid tumors, approved in the US
  • FoundationOne CDx is a sequencing-based in vitro diagnostic device, identify patients benefitted from targeted therapies with their approved therapeutic product labeling and has received FDA’s approval for all solid tumors

Click here to read full press release/ article | Ref: Bayer | Image: Twitter